See more : Miraial Co., Ltd. (4238.T) Income Statement Analysis – Financial Results
Complete financial analysis of DermTech, Inc. (DMTKQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DermTech, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Dongwoon Anatech Co., Ltd. (094170.KQ) Income Statement Analysis – Financial Results
- Sysgration Ltd. (5309.TWO) Income Statement Analysis – Financial Results
- Muthoot Finance Limited (MUTHOOTFIN.BO) Income Statement Analysis – Financial Results
- XRApplied Technologies Inc. (XRAPF) Income Statement Analysis – Financial Results
- Warner Bros. Discovery, Inc. (DISCB) Income Statement Analysis – Financial Results
DermTech, Inc. (DMTKQ)
About DermTech, Inc.
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.30M | 14.52M | 11.84M | 5.89M | 3.36M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.02M | 13.87M | 10.56M | 5.98M | 3.30M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 276.00K | 647.00K | 1.27M | -96.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 1.80% | 4.46% | 10.76% | -1.63% | 1.78% | 0.00% | 0.00% | 0.00% |
| Research & Development | 15.24M | 24.05M | 16.26M | 5.29M | 2.50M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 43.78M | 36.09M | 24.84M | 13.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 45.00M | 58.67M | 37.58M | 16.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 88.78M | 94.76M | 62.41M | 29.90M | 15.17M | 306.24K | 60.00 | 2.73K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -355.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 104.02M | 118.81M | 78.67M | 35.19M | 17.67M | 306.24K | 60.00 | 2.73K |
| Cost & Expenses | 119.04M | 132.68M | 89.24M | 41.17M | 20.97M | 306.24K | 60.00 | 2.73K |
| Interest Income | 2.85M | 1.34M | 151.00K | 40.00K | 0.00 | 1.21M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.85M | 4.46M | 2.30M | 486.00K | 89.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -97.89M | -113.71M | -75.10M | -34.80M | -17.38M | 856.41K | -60.00 | -2.73K |
| EBITDA Ratio | -639.99% | -783.20% | -634.41% | -591.38% | -520.69% | 0.00% | 0.00% | 0.00% |
| Operating Income | -103.74M | -118.17M | -77.40M | -35.29M | -17.61M | -306.24K | -60.00 | -2.73K |
| Operating Income Ratio | -678.21% | -813.92% | -653.81% | -599.64% | -523.34% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.85M | 1.48M | -937.00K | -1.19M | -2.53M | 1.16M | 0.00 | -3.00 |
| Income Before Tax | -100.89M | -116.68M | -78.34M | -36.48M | -19.69M | 856.41K | -60.00 | -2.73K |
| Income Before Tax Ratio | -659.57% | -803.71% | -661.72% | -619.83% | -585.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -100.89M | -116.68M | -78.34M | -36.48M | -19.69M | 856.41K | -60.00 | -2.73K |
| Net Income Ratio | -659.57% | -803.71% | -661.72% | -619.83% | -585.29% | 0.00% | 0.00% | 0.00% |
| EPS | -3.09 | -3.88 | -2.71 | -2.15 | -2.81 | 0.09 | 0.00 | 0.00 |
| EPS Diluted | -3.09 | -3.88 | -2.71 | -2.15 | -2.81 | 0.09 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M | 9.08M | 9.27M | 9.27M |
| Weighted Avg Shares Out (Dil) | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M | 9.08M | 9.27M | 9.27M |
Source: https://incomestatements.info
Category: Stock Reports